79399473

Information

• Trademark
• 79399473

• Source

• Serial Number

  79399473

• International Classifications

  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  May 02, 2024
  a year ago

• Transaction Date

  July 17, 2025
  7 months ago

• Status Date

  July 16, 2025
  7 months ago

• Published for Opposition Date

  August 05, 2025
  7 months ago

• Location Date

  July 16, 2025
  7 months ago

• Status Code

  681

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  BERGER, MAGDALENA

• Attorney Docket Number

  B17012002100

  Attorney Name

  Christina M. Licursi

  Law Office Assigned Location Code

  N50

• Owners

  • BicycleTx Limited

Case File Statements

• DM0000: The mark consists of a stylized representation of a bicycle.
• GS0051: Pharmaceuticals for use in oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical preparations for suppressing tumors; pharmaceutical products for the treatment of cancer; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of ophthalmology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and prevention of respiratory disease; pharmaceutical products and preparations for the treatment and prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and prevention of metabolic disease; pharmaceutical products and preparations for the treatment and prevention of viral infections; pharmaceutical products and preparations for use in diagnostics and imaging, namely, clinical imaging agents; pharmaceutical products and preparations for the treatment and prevention of renal disease; pharmaceutical products and preparations for the treatment and prevention of gastrointestinal disease; pharmaceutical products and preparations for the treatment and prevention of muscular skeletal disease
• GS0441: Medical services; medical testing for diagnostic or treatment purposes; healthcare services; pharmaceutical services, namely, pharmaceutical compounding services; medical consulting services; advisory services relating to pharmaceuticals; consultancy and information services relating to pharmaceuticals, namely, pharmaceutical consultation and providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services in the field of oncology; medical services in the field of ophthalmology; medical services in the field of neurology; medical services in the field of anti-infectives; medical services in connection with respiratory disease; medical services in connection with cardiovascular disease; medical services in connection with metabolic disease; medical services in connection with the treatment and/or prevention of viral infections; medical services in connection with diagnostics and imaging; medical services in connection with renal disease; medical services in connection with gastrointestinal disease; medical services in connection with muscular skeletal disease; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti- infectives; pharmaceutical compounding services in connection with respiratory disease; pharmaceutical compounding services in connection with cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and/or prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease; information, consultancy and advisory services relating to the aforesaid
• GS0421: Scientific and technological services and research and design relating thereto, namely, scientific research, new product design services, and new study design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; medical research services, namely, industrial analysis and research services in the field of medicine; pharmaceutical research and development services; medical research and development services; pharmaceutical research services, namely, pharmaceutical testing and clinical trials; scientific research in the nature of conducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of medical diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; scientific research consulting, namely, providing information consultancy and advisory services relating to the aforesaid in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents

Case File Event Statements

• 7/11/2024 - a year ago

  1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR

• 7/12/2024 - a year ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 7/12/2024 - a year ago

  3 - APPLICATION FILING RECEIPT MAILED Type: MAFR

• 9/19/2024 - a year ago

  7 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA

• 9/19/2024 - a year ago

  8 - TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Type: ECDR

• 9/19/2024 - a year ago

  6 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP

• 9/19/2024 - a year ago

  5 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN

• 9/19/2024 - a year ago

  4 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR

• 11/16/2024 - a year ago

  9 - ASSIGNED TO EXAMINER Type: DOCK

• 11/25/2024 - a year ago

  10 - NON-FINAL ACTION WRITTEN Type: CNRT

• 11/26/2024 - a year ago

  11 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR

• 12/10/2024 - a year ago

  13 - NON-FINAL ACTION WRITTEN Type: CNRT

• 12/10/2024 - a year ago

  12 - NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW Type: RFWR

• 12/11/2024 - a year ago

  14 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR

• 1/2/2025 - a year ago

  16 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS

• 1/2/2025 - a year ago

  15 - REFUSAL PROCESSED BY MPU Type: RFRR

• 1/17/2025 - a year ago

  17 - REFUSAL PROCESSED BY IB Type: RFNT

• 3/26/2025 - 11 months ago

  19 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN

• 3/26/2025 - 11 months ago

  22 - TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Type: ECDR

• 3/26/2025 - 11 months ago

  20 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP

• 3/26/2025 - 11 months ago

  18 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR

• 3/26/2025 - 11 months ago

  23 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA

• 3/26/2025 - 11 months ago

  21 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA

• 6/2/2025 - 9 months ago

  25 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 6/2/2025 - 9 months ago

  24 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 6/2/2025 - 9 months ago

  26 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 6/26/2025 - 8 months ago

  27 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 6/26/2025 - 8 months ago

  29 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 6/26/2025 - 8 months ago

  30 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 6/26/2025 - 8 months ago

  28 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 6/30/2025 - 8 months ago

  31 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA